Experienced in Tetanus

Galia Rahav

Sheba Med Ctr, 
Ramat Gan, TA, IL 
Experienced in Tetanus
Sheba Med Ctr, 
Ramat Gan, TA, IL 
OverviewLocationsClinical Research

Overview

Galia Rahav practices in Ramat Gan, Israel. Ms. Rahav is rated as an Experienced expert by MediFind in the treatment of Tetanus. Her top areas of expertise are Strep Throat, Salmonella Enterocolitis, Severe Acute Respiratory Syndrome (SARS), Heart Transplant, and Kidney Transplant.

Her clinical research consists of co-authoring 180 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Tetanus.

Gender
Female

Locations

Sheba Med Ctr, Ramat Gan, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Drug
Study Drug: VB-201
Study Phase: Phase 2
A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).
A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).
Enrollment Status: Terminated
Publish Date: December 26, 2019
Intervention Type: Biological, Other
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

180 Total Publications

Impact of asymptomatic Clostridioides difficile carriage screening on antibiotic stewardship among hospitalized patients.
Impact of asymptomatic Clostridioides difficile carriage screening on antibiotic stewardship among hospitalized patients.
Journal: Infection control and hospital epidemiology
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rahav's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile